Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, ...
With enterprise architecture teams facing growing pressure to demonstrate business value, legacy frameworks often stall when ...
Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA™ (gepirone) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results